|Assessment of treatment coverage during mass drug administration (MDA) 1-6|
|MDA no.||Time of MDA||Reported coverage for the district in%*||Surveyed coverage in%|
|Community study#||School study§|
* Official NLFEP coverage for eligible individuals in Tanga District, where the three study villages and ten study schools are located.
# Assessed by interviews shortly after each MDA in the study communities (975, 1009, 883, 930, 778 and 1462 individuals aged ≥ 5 years interviewed after MDA 1-6, respectively).
§ Assessed by interviews shortly after each MDA in the 10 study schools (859, 676, 776, 836, 704 and 746 Standard 1 pupils interviewed after MDA 1-6, respectively).
Simonsen et al.
Simonsen et al. BMC Infectious Diseases 2013 13:335 doi:10.1186/1471-2334-13-335